KIOM-79 prevents S100b-induced TGF-β1 and fibronectin expression in mouse mesangial cells

Journal of Ethnopharmacology

Volumn 125, Issue 3, 2009, Pages 374-379

  Jung, Dong Ho ^a   Kim, Young Sook ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Diabetic nephropathy; Euphorbia pekinensis; Glycyrrhiza uralensis; KIOM 79; Magnolia officinalis; Pueraria lobata

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; EUPHORBIA EXTRACT; FIBRONECTIN; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KIOM 79; MAGNOLIA EXTRACT; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN S100B; PUERARIA EXTRACT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DATA ANALYSIS; DIABETIC NEPHROPATHY; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID PEROXIDATION; MESANGIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRONECTINS; MALONDIALDEHYDE; MESANGIAL CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLANT EXTRACTS; RNA, MESSENGER; S100 PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EUPHORBIA PEKINENSIS; GLYCYRRHIZA URALENSIS; MAGNOLIA OFFICINALIS; PUERARIA MONTANA VAR. LOBATA;

EID: 69949100561     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2009.08.002     Document Type: Article

References (35)

1. Alarcon-Aguilara F.J., Roman-Ramos R., Perez-Gutierrez S., Aguilar-Contreras A., Contreras-Weber C.C., and Flores-Saenz J.L. Study of the anti-hyperglycemic effect of plants used as antidiabetics. Journal of Ethnopharmacology 61 (1998) 101-110
2. Alderson N.L., Chachich M.E., Youssef N.N., Beattie R.J., Nachtigal M., Thorpe S.R., and Baynes J.W. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney International 63 (2003) 2123-2133
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 4 (2005) 1615-1625
4. Bruijn J.A., Roos A., de Geus B., and de Heer E. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. The Journal of Laboratory and Clinical Medicine 123 (1994) 34-47
5. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 4 (2001) 1957-1972
6. Figarola J.L., Loera S., Weng Y., Shanmugam N., Natarajan R., and Rahbar S. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51 (2008) 882-891
7. Gruden G., Perin P.C., and Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Current Diabetes Reviews 1 (2005) 27-40
8. Huebschmann A.G., Vlassara H., Regensteiner J.G., and Reusch J. Diabetes and advanced glycoxidation end products. Annual Review of Diabetes (2007) 51-63
9. Hur, J., Donguibogam Parallel Version, 1999. Committee of Dongui Bogam Translation. Bupin Publishes Co., Seoul, Korea, p. 1979.
10. Jeon Y.J., Li M.H., Lee K.Y., Kim J.S., You H.J., Lee S.K., Sohn H.M., Choi S.J., Koh J.W., and Chang I.Y. KIOM-79 inhibits LPS-induced iNOS gene expression by blocking NF-kappaB/Rel and p38 kinase activation in murine macrophages. Journal of Ethnopharmacology 108 (2006) 38-45
11. Kang K.A., Lee K.H., Kim S.Y., Kim H.S., Kim J.S., and Hyun J.W. Cytoprotective effects of KIOM-79 on streptozotocin induced cell damage by inhibiting ERK and AP-1. Biological and Pharmaceutical Bulletin 30 (2007) 852-858
12. Kim C.S., Sohn E.J., Kim Y.S., Jung D.H., Jang D.S., Lee Y.M., Kim D.H., and Kim J.S. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Journal of Ethnopharmacology 111 (2007) 240-247
13. Kim J., Kim C.-S., Sohn E.J., Kim O.S., Lee Y.M., Jang D.S., and Kim J.S. Effects of KIOM-79 on diabetic retinopathy in Zucker diabetic fatty rat. Diabetes 57 (2008) A572
14. Kim Y.S., Kim B.C., Song C.Y., Hong H.K., Moon K.C., and Lee H.S. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. The Journal of Laboratory and Clinical Medicine 138 (2001) 59-68
15. Kim Y.S., Lee Y.M., Kim C.-S., Sohn E.J., Jang D.S., and Kim J.S. Inhibitory effect of KIOM-79 (an herbal prescription) on AGEs formation and expressions of Type IV collagen and TGF-beta1 in STZ-induced diabetic rats. Korean Journal of Pharmacognosy 37 (2006) 103-106
16. Kim Y.S., Jung D.H., Kim N.H., Lee Y.M., Jang D.S., Song G.Y., and Kim J.S. KIOM-79 inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. Journal of Ethnopharmacology 112 (2007) 166-172
17. Kim Y.S., Kim N.H., Jung D.H., Sohn E.J., Lee Y.M., Jang D.S., and Kim J.S. Effect of KIOM-79 on expression of TGF-beta2 in human lens epithelial cells under hyperglycemic conditions and in an in vitro rat model of cataract. Diabetes 57 (2008) A114
18. Kim Y.S., Kim N.H., Jung D.H., Jang D.S., Lee Y.M., Kim J.M., and Kim J.S. Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. European Journal of Pharmacology 594 (2008) 18-25
19. Kim, Y.S., Kim, J., Kim, C.-S., Sohn, E.J., Lee, Y.M., Jeong, I.-H., Kim, H., Jang, D.S., Kim, J.S., in press. KIOM-79, an inhibitor of AGEs-protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evidence-based Complementary and Alternative Medicine.
20. Li W.L., Zheng H.C., Bukuru J., and De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. Journal of Ethnopharmacology 92 (2004) 1-21
21. Lin C.L., Wang F.S., Kuo Y.R., Huang Y.T., Huang H.C., Sun Y.C., and Kuo Y.H. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney International 69 (2006) 1593-1600
22. Manuel Y., Keenoy B., Vertommen J., and De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes, Nutrition & Metabolism 12 (1999) 256-263
23. Odetti P., Pesce C., Traverso N., Menini S., Maineri E.P., Cosso L., Valentini S., Patriarca S., Cottalasso D., Marinari U.M., and Pronzato M.A. Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes 52 (2003) 499-505
24. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., and Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. American Journal of Physiology. Renal Physiology 292 (2007) F1141-F1150
25. Peppa M., Brem H., Cai W., Zhang J.G., Basgen J., Li Z., Vlassara H., and Uribarri J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). American Journal of Nephrology 26 (2006) 430-436
26. Qian Y., Feldman E., Pennathur S., Kretzler M., and Brosius F.C. 3rd: From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 7 (2008) 1439-1445
27. Reeves W.B., and Andreoli T.E. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 7667-7669
28. Roberts A.B., McCune B.K., and Sporn M.B. TGF-beta: regulation of extracellular matrix. Kidney International 141 (1992) 557-559
29. Scivittaro V., Ganz M.B., and Weiss M.F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. American Journal of Physiology. Renal Physiology 278 (2000) F676-683
30. Sharma K., and Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44 (1995) 1139-1146
31. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., Penfold S.A., Bach L.A., Cooper M.E., and Forbes J.M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57 (2008) 460-469
32. Tojo A., Asaba K., and Onozato M.L. Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opinion on Therapeutic Targets 11 (2007) 1011-1018
33. Yu L., Border W.A., Huang Y., and Noble N.A. TGF-beta isoforms in renal fibrogenesis. Kidney International 64 (2003) 844-856
34. Ziegler D., Reljanovic M., Mehnert H., and Gries F.A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Experimental and Clinical Endocrinology & Diabetes 107 (1999) 421-430
35. Zimmer D.B., Chessher J., Wilson G.L., and Zimmer W.E. S100A1 and S100B expression and target proteins in type I diabetes. Endocrinology 138 (1997) 5176-5183